PUBLISHER: GlobalData | PRODUCT CODE: 2094951
PUBLISHER: GlobalData | PRODUCT CODE: 2094951
Hepatitis C Virus: Epidemiology Report and Forecast to 2035
Hepatitis C is an inflammatory liver disease caused by the hepatitis C virus (HCV). HCV primarily spreads through direct blood contact, which can happen via needle/syringe sharing in people who inject drugs, unscreened blood transfusions and unsterilized medical equipment, and sexual contact involving blood. Additionally, vertical transmission of HCV can occur (Public Health England, 2018). Many people with hepatitis C are asymptomatic and unaware that they have the infection, with only approximately a quarter of patients exhibiting symptoms, including fatigue, abdominal pains, fever, nausea, vomiting, and jaundice (Fasano et al., 2024; NHS, 2021a). Acute infection refers to infections lasting for up to six months after infection, and of these infections approximately 30% undergo spontaneous clearance. The remaining 70% of cases that last over six months develop into chronic hepatitis C, which can result in cirrhosis and hepatocellular carcinoma (HCC) if left untreated (Fasano et al., 2024; NHS, 2021a).
Hepatitis C is an inflammatory liver disease caused by the hepatitis C virus (HCV). HCV primarily spreads through direct blood contact, which can happen via needle/syringe sharing in people who inject drugs (PWID), unscreened blood transfusions and unsterilized medical equipment, and sexual contact involving blood. Additionally, vertical transmission of HCV can occur (Public Health England, 2018). Many people with hepatitis C are asymptomatic and unaware that they have the infection, with only approximately a quarter of patients exhibiting symptoms, including fatigue, abdominal pains, fever, nausea, vomiting, and jaundice (Fasano et al., 2024; NHS, 2021a). Acute infection refers to infections lasting for up to six months after infection, and of these infections approximately 30% undergo spontaneous clearance. The remaining 70% of cases that last over six months develop into chronic hepatitis C, which can result in cirrhosis and hepatocellular carcinoma (HCC) if left untreated (Fasano et al., 2024; NHS, 2021a). According to the World Health Organization (WHO), an estimated 50 million people have chronic hepatitis C infection globally, with approximately one million cases occurring per year (WHO, 2025a).
Scope
- The Hepatitis C Virus: Epidemiology Report and Forecast Model provide an overview of the risk factors, comorbidities, and global trends of Hepatitis C in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
- The report includes a 10-year epidemiology forecast for the diagnosed incident cases of acute hepatitis C and diagnosed prevalent cases of chronic hepatitis C. The diagnosed incident cases of acute hepatitis C among men and women are segmented by sex, age (three years and older), genotype (genotypes 1-6), and cases that have been treated.
- The diagnosed prevalent cases of chronic hepatitis C are segmented by sex, age (three years and older), genotype, cirrhosis status, coinfection (hepatitis B and HIV), and cases that have been treated. Additionally, the report provides estimated incident cases of acute hepatitis C and total prevalent cases of chronic hepatitis C.
Reasons to Buy
The Hepatitis C Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global Hepatitis C markets.
- Quantify patient populations in the global Hepatitis C markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Hepatitis C therapeutics in each of the markets covered.
- Understand magnitude of the Hepatitis C population by age, sex, genotype, cirrhosis status, coinfection, and treated status.
Table of Contents
Table of Contents
List of Tables
List of Figures
1 Executive Summary
- 1.1 Catalyst
- 1.2 Related reports
- 1.3 Upcoming reports
2 Epidemiology
- 2.1 Disease background
- 2.2 Risk factors and comorbidities
- 2.3 Global and historical trends
- 2.4 8MM forecast methodology
- 2.4.1 Sources
- 2.4.2 Forecast assumptions and methods
- 2.4.3 Forecast assumptions and methods: diagnosed incident cases of acute hepatitis C
- 2.4.4 Forecast assumptions and methods: diagnosed incident cases of acute hepatitis C by genotype, diagnosed prevalent cases of chronic hepatitis C by genotype
- 2.4.5 Forecast assumptions and methods: diagnosed incident cases of acute hepatitis C that have been treated
- 2.4.6 Forecast assumptions and methods: estimated incident cases of acute hepatitis C
- 2.4.7 Forecast assumptions and methods: total prevalent cases of chronic hepatitis C
- 2.4.8 Forecast assumptions and methods: diagnosed prevalent cases of chronic hepatitis C
- 2.4.9 Forecast assumptions and methods: diagnosed prevalent cases of chronic hepatitis C by cirrhosis status
- 2.4.10 Forecast assumptions and methods: diagnosed prevalent cases of chronic hepatitis C by coinfection
- 2.4.11 Forecast assumptions and methods: diagnosed prevalent cases of chronic hepatitis C that have been treated
- 2.5 Epidemiological forecast for hepatitis C (2025-35)
- 2.5.1 Diagnosed incident cases of acute hepatitis C
- 2.5.2 Age-specific diagnosed incident cases of acute hepatitis C
- 2.5.3 Sex-specific diagnosed incident cases of acute hepatitis C
- 2.5.4 Diagnosed incident cases of acute hepatitis C by genotype
- 2.5.5 Diagnosed incident cases of acute hepatitis C that have been treated
- 2.5.6 Estimated incident cases of acute hepatitis C
- 2.5.7 Total prevalent cases of chronic hepatitis C
- 2.5.8 Age-specific total prevalent cases of chronic hepatitis C
- 2.5.9 Sex-specific total prevalent cases of chronic hepatitis C
- 2.5.10 Diagnosed prevalent cases of chronic hepatitis C
- 2.5.11 Age-specific diagnosed prevalent cases of chronic hepatitis C
- 2.5.12 Sex-specific diagnosed prevalent cases of chronic hepatitis C
- 2.5.13 Diagnosed prevalent cases of chronic hepatitis C by genotype
- 2.5.14 Diagnosed prevalent cases of chronic hepatitis C by cirrhosis status
- 2.5.15 Diagnosed prevalent cases of chronic hepatitis C by coinfection
- 2.5.16 Diagnosed prevalent cases of chronic hepatitis C that have been treated
- 2.6 Discussion
- 2.6.1 Epidemiological forecast insight
- 2.6.2 Limitations of the analysis
- 2.6.3 Strengths of the analysis
3 Appendix
- 3.1 Bibliography
- 3.2 Primary research - high-prescriber survey
- 3.3 About the Authors
- 3.3.1 Epidemiologist
- 3.3.2 Reviewers
- 3.3.3 Vice President of Disease Intelligence and Epidemiology
- 3.3.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence
- About GlobalData
- Contact Us
List of Table
- Table 1: Summary of newly added data types
- Table 2: Summary of updated data types
- Table 3: HCV genotypes and subtypes
- Table 4: Risk factors and comorbidities for hepatitis C
- Table 5: High-prescribing physicians surveyed, by country
List of Figure
- Figure 1: 8MM, diagnosed incident cases of acute hepatitis C, men and women, N, ages >=3 years, 2025 and 2035
- Figure 2: 8MM, diagnosed prevalent cases of chronic hepatitis C, men and women, N, ages >=3 years, 2025 and 2035
- Figure 3: 8MM, diagnosed incidence of acute hepatitis C, men and women, cases per 100,000 population, ages >=3 years, 2015-35
- Figure 4: 8MM, diagnosed prevalence of chronic hepatitis C, men and women, %, ages >=3 years, 2015-35
- Figure 5: 8MM, sources used and not used to forecast the diagnosed incident cases of acute hepatitis C
- Figure 6: 8MM, sources used and not used to forecast the diagnosed incident cases of acute hepatitis C by genotype, and diagnosed prevalent cases of chronic hepatitis C by genotype
- Figure 7: 8MM, sources used to forecast the estimated incident cases of acute hepatitis C
- Figure 8: 8MM, sources used and not used to forecast the diagnosed prevalent cases of chronic hepatitis C, and the total prevalent cases of chronic hepatitis C
- Figure 9: 8MM, sources used to forecast the diagnosed prevalent cases of chronic hepatitis C by cirrhosis status
- Figure 10: 8MM, sources used to forecast the diagnosed prevalent cases of chronic hepatitis C by coinfection
- Figure 11: 8MM, diagnosed incident cases of acute hepatitis C, N, men and women, ages >=3 years, 2025
- Figure 12: 8MM, diagnosed incident cases of acute hepatitis C by age, N, men and women, 2025
- Figure 13: 8MM, diagnosed incident cases of acute hepatitis C by sex, N, ages >=3 years, 2025
- Figure 14: 8MM, diagnosed incident cases of acute hepatitis C by genotype, N, men and women, ages >=3 years, 2025
- Figure 15: 8MM, diagnosed incident cases of acute hepatitis C that had been treated, N, men and women, ages >=3 years, 2025
- Figure 16: 8MM, estimated incident cases of acute hepatitis C, N, men and women, ages >=3 years, 2025
- Figure 17: 8MM, total prevalent cases of chronic hepatitis C, N, men and women, ages >=3 years, 2025
- Figure 18: 8MM, total prevalent cases of chronic hepatitis C by age, N, men and women, 2025
- Figure 19: 8MM, total prevalent cases of chronic hepatitis C by sex, N, >=3 years, 2025
- Figure 20: 8MM, diagnosed prevalent cases of chronic hepatitis C, N, men and women, ages >=3 years, 2025
- Figure 21: 8MM, diagnosed prevalent cases of chronic hepatitis C by age, N, men and women, 2025
- Figure 22: 8MM, diagnosed prevalent cases of chronic hepatitis C by sex, N, ages >=3 years, 2025
- Figure 23: 8MM, diagnosed prevalent cases of chronic hepatitis C by genotype, N, men and women, ages >=3 years, 2025
- Figure 24: 8MM, diagnosed prevalent cases of chronic hepatitis C by cirrhosis status, N, men and women, ages >=3 years, 2025
- Figure 25: 8MM, diagnosed prevalent cases of chronic hepatitis C by coinfection, N, men and women, ages >=3 years, 2025
- Figure 26: 8MM, diagnosed prevalent cases of chronic hepatitis C that have been treated, N, men and women, ages >=3 years, 2025
